TipRanks (Wed, 8-Apr 6:25 AM ET)
Globe Newswire (Tue, 7-Apr 8:50 AM ET)
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
Globe Newswire (Wed, 25-Mar 4:05 PM ET)
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering
Globe Newswire (Tue, 24-Mar 7:00 AM ET)
Outlook Therapeutics Announces Proposed Public Offering
Globe Newswire (Mon, 23-Mar 5:30 PM ET)
Globe Newswire (Mon, 16-Mar 8:05 AM ET)
Globe Newswire (Thu, 5-Mar 4:15 PM ET)
Globe Newswire (Thu, 19-Feb 9:00 AM ET)
Globe Newswire (Tue, 17-Feb 8:05 AM ET)
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
Globe Newswire (Wed, 11-Feb 8:45 AM ET)
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Outlook Therapeutics trades on the NASDAQ stock market under the symbol OTLK.
As of April 13, 2026, OTLK stock price was flat at $0.25 with 1,147,337 million shares trading.
OTLK has a beta of 1.91, meaning it tends to be more sensitive to market movements. OTLK has a correlation of 0.02 to the broad based SPY ETF.
OTLK has a market cap of $26.15 million. This is considered a Sub-Micro Cap stock.
Last quarter Outlook Therapeutics reported $-1 million in Revenue and -$.22 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$.05.
In the last 3 years, OTLK traded as high as $40.60 and as low as $.16.
The top ETF exchange traded funds that OTLK belongs to (by Net Assets): VTI, VXF, IWC.
OTLK has underperformed the market in the last year with a return of -79.8%, while the SPY ETF gained +31.5%. In the last 3 month period, OTLK fell short of the market, returning -57.6%, while SPY returned -1.4%. However, in the most recent 2 weeks OTLK has outperformed the stock market by returning +20.1%, while SPY returned +7.6%.
OTLK support price is $.23 and resistance is $.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OTLK shares will trade within this expected range on the day.
